Gao Manli, Geng Hao, Wu Peng, Dong Jianjian, Li Hai, Xu Chenchen, Li Bo, Han Yongzhu, Cheng Nan
Anhui University of Chinese Medicine, Hefei, China.
Anhui University of Chinese Medicine, Hefei, China; Institute of Intelligent Machines, Chinese Academy of Sciences, Hefei, China; Department of Biophysics, University of Science and Technology of China, Hefei, China.
Ann Palliat Med. 2020 Sep;9(5):2872-2885. doi: 10.21037/apm-20-301. Epub 2020 Aug 10.
Gandou decoction (GDD) has been widely used in the treatment of Wilson disease (WD) for decades. It is optimized from the Dahuanghuanglianxiexin decoction, Yinchenhao decoction, and Huanglianjiedu decoction. It was first reported in the Treatise on Febrile and Miscellaneous Diseases and A Handbook of Prescriptions for Emergencies published in the Eastern Han Dynasty and the Eastern Jin Dynasty respectively. Hepatic injury is one of the most severe complications of WD. The current study aimed to explore the hepatic-protection effects of GDD and its exact therapeutic target, with a particular focus on the expression of oxidative stress and the Wnt/β-catenin pathway.
Hepatic injury was induced in a copper-loaded rat model using the intragastric administration of copper(II) sulfate pentahydrate (CuSO4·5H2O). The water extract of GDD (0.4 g/kg/d) was administered twice a day for 4 weeks. Copper content and alanine aminotransferase (ALT) level, structural observation under the microscope, and immunohistochemical analysis of liver tissue were performed after the final administration. Moreover, the expression of β-catenin, GSK3β, Dishevelled-3, c-Myc, and p-GSK3β of liver tissue were detected to explore the relationship between the hepatic protection of GDD and the Wnt/ β-catenin signal pathway of GDD. We also stimulated the rat hepatic cell line BRL-3A with CuSO4·5H2O to establish a hepatic injury cytomodel. GDD serum at a concentration of 20% was administered into the model cell for 24 h. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and flow cytometry were performed to detect cell viability, mitochondrial membrane potential (MMP), and the expression of reactive oxygen species (ROS). Meanwhile, the expression of the Wnt/β-catenin signal pathway-related proteins was evaluated.
GDD reduced copper and ALT while inhibiting oxidative stress and the degeneration and necrosis of liver tissue and hepatocytes. Treatment with GDD improved cell viability and MMP while suppressing the ROS level. Furthermore, GDD rectified the expression of Wnt/β-catenin signal pathway-related proteins in both livers of the copper-loaded and copper-stimulated BRL-3A cell lines.
GDD had apparent therapeutic effects on the hepatic injury of copper-loaded rats and copper-stimulated BRL-3A cells. Its mechanism is related to its regulatory effect on the Wnt/β-catenin pathway rectification and oxidative stress antagonism.
decades 来,甘露饮(GDD)已广泛用于治疗威尔逊病(WD)。它是由大黄黄连泻心汤、茵陈蒿汤和黄连解毒汤优化而来。它分别在东汉和东晋出版的《伤寒杂病论》和《肘后备急方》中首次被报道。肝损伤是 WD 最严重的并发症之一。本研究旨在探讨 GDD 的肝保护作用及其确切的治疗靶点,特别关注氧化应激和 Wnt/β-连环蛋白信号通路的表达。
通过灌胃给予五水硫酸铜(CuSO4·5H2O)在铜负荷大鼠模型中诱导肝损伤。GDD 水提取物(0.4 g/kg/d)每天给药两次,持续 4 周。末次给药后进行肝脏铜含量和丙氨酸氨基转移酶(ALT)水平检测、显微镜下结构观察以及肝组织免疫组化分析。此外,检测肝组织中 β-连环蛋白、糖原合成酶激酶 3β(GSK3β)、散乱蛋白 3(Dishevelled-3)、c-Myc 和磷酸化 GSK3β(p-GSK3β)的表达,以探讨 GDD 的肝保护作用与 GDD 的 Wnt/β-连环蛋白信号通路之间的关系。我们还用 CuSO4·5H2O 刺激大鼠肝细胞系 BRL-3A 建立肝损伤细胞模型。将浓度为 20%的 GDD 血清加入模型细胞中作用 24 h。采用噻唑蓝(MTT)法和流式细胞术检测细胞活力、线粒体膜电位(MMP)和活性氧(ROS)的表达。同时,评估 Wnt/β-连环蛋白信号通路相关蛋白的表达。
GDD 降低了铜含量和 ALT,同时抑制了氧化应激以及肝组织和肝细胞的变性和坏死。GDD 治疗提高了细胞活力和 MMP,同时降低了 ROS 水平。此外,GDD 纠正了铜负荷大鼠肝脏和铜刺激的 BRL-3A 细胞系中 Wnt/β-连环蛋白信号通路相关蛋白 的表达。
GDD 对铜负荷大鼠和铜刺激的 BRL-3A 细胞的肝损伤具有明显的治疗作用。其机制与其对 Wnt/β-连环蛋白信号通路的调节作用以及氧化应激拮抗作用有关。